Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

The FDA approval for Enspryng is based on the results from the two 96-week clinical trials, the SAkuraStar and SAkuraSky. Credit: Business Wire.



  • Enspryng (satralizumab-mwge)
  • Enspryng (satralizumab-mwge)
  • Enspryng (satralizumab-mwge)